OUR CHALLENGE
Identify the right patients at the right time
Breast cancer is the most frequently diagnosed cancer among women worldwide, with over 2.26 million new cases and nearly 685,000 deaths every year. Despite these alarming statistics, early detection and appropriate therapeutic follow-up significantly improves survival rates. (1)
Belgium and The Netherlands are reported to have the highest incidence rate of breast cancer worldwide. The Institut Jules Bordet highlights a concerning statistic in Belgium: one in eight women is expected to develop breast cancer during her lifetime. These alarming rates have also been observed in the United Kingdom and in the United States. This emphasizes the urgent need for innovative diagnostics and treatments to support the global fight against breast cancer. (2)
Nevertheless, with early detection in its initial, localized stages and advancements in treatment methodologies, survival rates for breast cancer are excepted to rise in forthcoming years. This optimism is fueled by ongoing research and innovations in oncology, heralding a hopeful outlook for patients worldwide.
References:
Maximize recovery: right treatment for the right patient at the right time
To maximize recovery chances, it is crucial to ensure patients get the right treatment at the right time. In the last decade, multiple targeted therapies have been introduced for (metastatic) breast cancer. While these targeted therapies are effective, their success depends on their timely administration to suitable patients.
The challenge lies in accurately identifying these patients with precise and specific diagnostic tools, which are currently lacking.
Currently, the determination of treatment strategies is predominately based on small tissue samples from biopsies. Not only are biopsies invasive and upsetting for patients, they also fail to provide whole-body insights, critical for accurate diagnosis.
Next to diagnosing patients, follow-up of patients throughout and post-treatment is vital. However, the effectiveness of existing monitoring tools is compromised by their invasiveness or reliance on broad, non-specific diagnostic approaches.
ABSCINT is pioneering the development of next-generation in vivo imaging diagnostic tools to enhance patient care, from the selection of the optimal treatment strategy to comprehensive monitoring and patient treatment follow-up. ABSCINT’s innovative diagnostics offer unparalleled specificity, accuracy, convenience and safety for both patients and healthcare workers.
